Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.39 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3037011 | 0.81 | SLC6A2 (0.61) | IDO1ACACBSLC6A2SLC6A3LMNA | |
| SCHEMBL2579982 | 0.80 | PTGS1 (0.57) | IDO1ESR1PTGS1PTGS2LMNA | |
| SCHEMBL10918313 | 0.78 | IDO1 (0.44) | IDO1ACACBSLC6A2SLC6A3 | |
| SCHEMBL19546067 | 0.76 | IDO1 (0.48) | IDO1ESR1ESR2ACACBPYCR1 | |
| SCHEMBL15820761 | 0.76 | SLC6A2 (0.68) | SLC6A2SLC6A3 | |
| SCHEMBL24848154 | 0.76 | IDO1 (0.48) | IDO1ESR1ESR2ACACBPYCR1 | |
| Hydrogen Peroxide SCHEMBL11174890 | 0.76 | PTGS1 (0.64) | ESR1PTGS1PTGS2LMNACYP2C9 | |
| SCHEMBL3371824 | 0.76 | ESR1 (0.48) | IDO1ESR1ESR2ACACBPYCR1 | |
| SCHEMBL18459578 | 0.76 | SLC6A2 (0.68) | SLC6A2SLC6A3 | |
| Hydrogen Peroxide SCHEMBL9581059 | 0.76 | PTGS1 (0.64) | ESR1PTGS1PTGS2LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364982-A1 | Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof | ONO Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100261641-A1 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| US-7498323-B2 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20070155713-A1 | Nitrogen-containing heterocyclic compounds and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| EP-1621540-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1619193-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-25 | — | — | EP | disclosed |
| CN-1189830-A | Substituted 1, 3-dioxan-5-ylamino-heterocyclic compounds, method for the production thereof and use thereof as pest control agents | HOECHST SCHERING AGREVO GMBH (DE) | 1998-08-05 | — | — | CN | disclosed |
| EP-0006992-A1 | 3-(p-Isopropyl-phenyl)-2-methyl-n-propyl amines, fungicides containing these compounds, a method for the preparation of said compounds and a method for combating fungi by using said compounds | BASF Aktiengesellschaft (DE) | 1980-01-23 | — | — | EP | disclosed |
| EP-0001809-A1 | Synergetic insecticidal and acaricidal mixtures | BASF Aktiengesellschaft (DE) | 1979-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261641-A1 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF | CCR1, CCR7, CCR3 | IDO1 350/4885ESR1 1740/4885ESR2 1771/4885 |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | CCR1, CCR7, CCR3 | IDO1 350/4885ESR1 1740/4885ESR2 1771/4885 |
| US-20070155713-A1 | Nitrogen-containing heterocyclic compounds and use thereof | NNMT, HLA-DRB1, NNT | IDO1 18/4885ESR1 517/4885ESR2 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.